Cysteamine Microparticles for Cystic Fibrosis Lung Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for cystic fibrosis-related lung diseases, particularly those involving mucous-rich environments, lack effective therapies for preventing and treating bacterial infections, and there is a need for novel approaches that can reduce antibiotic usage while enhancing treatment efficacy.
Innovation Solution
Microparticles comprising sulfur-containing compounds like cysteamine or cystamine, or their pharmaceutically acceptable salts, hydrates, or esters, are developed for targeted delivery in lung diseases, with specific particle sizes and stabilizing agents such as trehalose or mannitol to improve formulation stability and aerosolization properties.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If antibiotics are used to treat bacterial infections in CF lung, then infection is controlled, but antibiotic resistance develops and treatment efficacy decreases
Solution Approach 1:
Cysteamine acts as an intermediary substance that disrupts bacterial iron metabolism and induces oxidative stress, providing an alternative mechanism to kill bacteria without using traditional antibiotics, thereby avoiding antibiotic resistance while maintaining treatment efficacy
Solution Approach 2:
The invention changes the therapeutic parameter from antibiotic-based treatment to cysteamine-based treatment that targets bacterial iron metabolism and redox balance, fundamentally altering the mechanism of action to bypass antibiotic resistance
2Reliability
If high doses of antibiotics are administered to treat CF lung infections, then bacterial burden is reduced, but side effects and toxicity increase
Solution Approach 1:
The microparticle formulation enables localized delivery of cysteamine directly to the lung tissue where Pseudomonas infections occur, achieving high local concentration for effective infection control while maintaining low systemic concentration to minimize toxicity
Solution Approach 2:
The invention skips the harmful phase of high-dose systemic antibiotic administration by using targeted microparticle delivery of cysteamine, which achieves therapeutic effect at lower doses through direct localization to infected lung tissue
3Adaptability or versatility
If conventional therapies are used for CF lung disease, then current standard of care is maintained, but treatment effectiveness in mucous-rich environments is insufficient
Solution Approach 1:
The invention uses composite microparticles combining cysteamine with suitable carriers and stabilizers (such as trehalose or mannitol), which enhance the adaptability of the therapy to mucous-rich CF lung environments while improving treatment effectiveness through sustained release and protected delivery
Solution Approach 2:
The microparticle formulation performs preliminary protection of cysteamine from degradation in the harsh CF lung environment, and preliminary targeting to deliver the active compound directly to infected sites, thereby improving both adaptability and effectiveness before the therapeutic action begins
Data Source
AI summary
The present invention provides microparticles comprising a sulphur-containing compound, such as cysteamine, or a pharmaceutically acceptable salt, hydrate or ester thereof. Also provided is a composition comprising the microparticles and a stabilizing agent.